Last reviewed · How we verify
NCT06812325
A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
Phase 3 trial testing VRDN-003 in Thyroid Eye Disease (TED) in 320 participants. Participants enrolled and being followed up; not accepting new ones.
22 April 2026
Quick facts
| Lead sponsor | Viridian Therapeutics, Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 320 |
| Start date | 3 February 2025 |
| Primary completion | 22 April 2026 |
| Estimated completion | 1 October 2026 |
| Sites | 64 locations across United States, France, Germany, Poland, Spain, Turkey (Türkiye), United Kingdom |
Drugs / interventions tested
- VRDN-003 — full drug profile →
- Placebo
Conditions studied
- Thyroid Eye Disease (TED) — all drugs for Thyroid Eye Disease (TED) →
Sponsor
Viridian Therapeutics, Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Thyroid Eye Disease (TED). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24
Time frame: Week 24
Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24
Sponsor's own description
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06812325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VRDN-003
Trials testing the same drug.
- NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
- NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
Other recruiting trials for Thyroid Eye Disease (TED)
Currently open trials in the same condition.
- NCT07257185 — MHB018A Treatment in Patients With Chronic Thyroid Eye Disease · Phase 3 · recruiting
- NCT07262476 — Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease · Phase 3 · recruiting
- NCT07211776 — A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease · Phase 3 · recruiting
- NCT06569758 — A Study of GenSci098 in Subjects With Active Thyroid Eye Disease · Phase 1 · recruiting
Other Viridian Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
- NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
- NCT06384547 — A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) · Phase 3 · completed
- NCT06179875 — An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 · Phase 3 · completed
- NCT06021054 — An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease ( · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06812325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Viridian Therapeutics, Inc.
- Last refreshed: 21 May 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06812325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing